13/308,658
`
`Incr tin bas d th rapi s off r
`(GLP—l) secretion.
`glucagon—like peptide—l
`a new option for treatment of type 2 diabetes. Saxagliptin,
`a potent,
`selective dipeptidyl peptidase—4 (DPP—4)
`inhibitor specifically designed
`for extended inhibition of the DPP—4 enzyme, causes increased endogenous
`GLP—l concentration In a phase 3 clin. trials program of 24 wk duration,
`saxagliptin was studied in 6 multicenter, multinational,
`randomized,
`controlled studies and in combination with 3 of the most commonly
`administered oral antidiabetic drugs: metformin, glyburide and a
`in Hb
`thiozolidinedione (TZD). Saxagliptin provided significant redns.
`HbAlc when given with netformin, glyburide,
`a TZD, or as monotherapy.
`Saxagliptin also reduced fasting plasma glucose and 2—h post—prandial
`glucose in each of these studies, and was weight and lipid neutral.
`Saxagliptin was we 1 to'erated and had a low risk of hypoglycemia when used
`as monotherapy.
`3§1§§E»S§~8, Saxagliptin
`RE: PAC (Pharmacological activity); THU (Therapeutic use); 3IOL
`(?io'ogical study); USES (Uses)
`increased
`(saxagliptin reduced dipeptidyl peptidase—4 enzyme,
`glucagon—like peptide—l concentration while alone or in combination with
`metformin, glyburide or thiazolidinedione reduced glycated Hb in
`patient with type 2 diabetes)
`36l442—04—8
`HCAPLUS
`
`2—Azabicyclo[3.l.0]hexane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.l.l3,7]dec—l—yl)acetyl]—,
`(lS,3S,5S)-
`(CA INDEX NAME)
`
`IT
`
`RN
`CN
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CITING REF COUNT:
`
`R«b«R«NC« COUNT:
`
`2
`
`24
`
`T{«R« ARE 2 CAP.JS RECORDS THAT CITE TIIS RECORD
`(2 CITINGS)
`T{«Rn AR« 24 CITnD R«b«RnNCfiS VAI.AE.E FOR THIS
`RECORD. ALL CITATIORS AVAILARLE IN Tin Rn FORMAT
`
`ANSWER 45 OF 87
`L49
`ACCESSION NU SER:
`DOCJ ENT WUMEER:
`
`COPYRIGHT 20l2 ACS on STN
`HCAPLUS
`20l0:658952
`HCAPLUS Full"teXt
`l53:52lll5
`
`TIT.?:
`
`AUT{OR(S).
`CO%?O%ATE SOURCE
`
`SOJRCE:
`
`PU?.ISH?R:
`
`Appraisal of saxagliptin as treatment of type 2
`diabetes
`
`ikhail, Nasser; Cope, Dennis
`?ndocrino'ogy Division, Olive View—UCLA Medical
`Cen:er, UCLA School of Medicine, USA
`Current Drug Therapy (20lO), 5(2), lll-ll7
`CODEN: CDTUBV;
`ISSN:
`I574-8855
`3en:ham Science Publishers Ltd.
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:27)(cid:28)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-|PR2016-01104- Ex. 1006, Part 1, p. 189 of 259
`
`60
`
`0189
`0189
`
`

`
`13/308,658
`
`HCAPLUS
`
`L‘J
`Journal; General Review
`DOCUMENT TYP :
`English
`EANGUAGE:
`28 May 2010
`ED
`En:ered STN:
`(DPP—4)
`The antidiabetic effect of the dipeptidyl peptidase 4
`A3
`A review.
`inhibitor saxagliptin.depends on the prolongation.of action of the 2 incretin
`hormones: glucagon.like peptide—l
`(GLP—l) andwgastric inhibitorgrpolypeptide
`(GIP) by preventing their rapid degradation by th
`nzym DPP 4. Th us of
`saxagliptin (5 mg/d)
`is associated with mean reduction in glycosylated Hb
`(HbAlc)
`levels ranging from 0.5% to 0.9% compared with baseline and 0.6 to
`0.8% compared with placebo after 24 wk of therapy.
`The main advantages of
`saxagliptin are the low risk of hypoglycemia,
`the neutral effect on body
`weight,
`the simplicity of use, and reassuring short—term safety profile.
`However,
`its mild—to—moderate efficacy,
`the lack of long—term safety and
`efficacy data, and relatively high cost represent its major limitations.
`Overall, saxagliptin may be a useful second agent for patients with type 2
`diabetes who are not optima"y controlled on metformin. This drug can also
`be used as monotherapy in patients with mild hyperglycemia who cannot
`tolerate metformin or a sulfonylurea (SU).
`3§1§§§"§§~8, Saxagliptin
`RE: PAC (Pharmacological activity); THU (Therapeutic use); 3IOL
`(3iological study); USES (Uses)
`(saxagliptin may be useful
`in treatment of patient with :ype 2
`diabetes)
`36l442—04—8
`
`IT
`
`RN
`
`CN
`
`2—Azabicyclo[3.l.0]heXane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.l.l3,7]dec—l—yl)acetyl]—,
`(lS,3S,5S)-
`(CA INDEX NAME)
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CITING REF COUNT:
`
`REFERENCE COUNT:
`
`l
`
`28
`
`T{ERE ARE l CAP.JS RECORDS THAT CITE T{IS RECORD
`(l CITINGS)
`T{ERE ARE 28 CITED REFERENCES AVAI.AE.E FOR THIS
`RECORD. ALL CITATIORS AVAILAELE IN T{E RE FORMAT
`
`L49
`
`ANSWER 46 OF 87
`
`HCAPLUS
`
`COPYRIGHT 20l2 ACS on STN
`
`ACCESSION NU EER:
`DOCJ ENT NUMEER:
`
`20l0:63904O HCAPLUS
`l53:494
`
`TIT.E:
`
`AUT{O%(S):
`L‘J
`COR?O%ATE SOURC :
`
`SOURCI:L‘J
`
`New treatments in the management of type 2 diabetes: a
`critical aopraisal of saxagliptin
`Gallwitz, 3aptist
`Dept. Medicine IV, Tuebingen University, Tuebingen,
`72076, Germany
`Diabetes,
`etabolic Syndrome and Obesity (2010), 3,
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:28)(cid:19)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-|PR2016-01104- Ex. 1006, Part 1, p. 190 of 259
`
`61
`
`0190
`0190
`
`

`
`13/308,658
`
`117-124
`CODEN: DMSOAD;
`
`ISSN: 1178-7007
`
`?J§LISHER:
`
`JRL: http://www.dovepress.com/getfi1e.php?f’7»
`
`Dove Medical Press Ltd.
`
`(online computer file)
`
`L‘J
`Journal; General Review;
`DOCUMENT TYPI:
`English
`EANGUAGE:
`«
`25 May 2010
`3
`«n:ered STN:
`A3
`A review. Saxagliptin is a novel dipeptidyl peptidase—4 inhibitor (DPP—4
`inhibitor) for the treatment of type 2 diabetes, with a duration profile for
`once daily dosing.
`It is highly selective for DPP—4 in comparison to other
`enzymes of the dipeptidyl.peptidase family.
`DPP—4 inhibitors elevate plasma
`concns. of the incretin hormones glucagon—like peptide—1 (GLP—1) and gastric
`inhibitory polypeptide (GIP). This effect results in a glucose-dependent
`stimulation of insulin secretion and an inhibition of glucagon secretion
`without an intrinsic risk for hypoglycemia.
`In comparison to sulfonylureas
`and.thiazolidinediones that promote weight gain, DPP—4 inhibitors are weight
`neutral. Saxagliptin.has been approved by the FDA.for the US and by the «MnA
`for Europe in.2009. Clin. trials showede1dose—dependent inhibition of D?P—4
`by saxagliptin.in doses ranging from.2.5 to 100 mg daily without serious side
`effects.
`Type 2 diabetic patients receiving 5 mg to 10 mg saxagliptin once
`daily had a significant lowering of HbA1c and glycemic parameters along with
`good tolerability and safety. Saxagliptin has demonstrated a good efficacy
`for glycemic parameters in various patient populations either in monotherapy
`or in combination with metformin and other oral antidiabetic drugs as well
`as a favorable cardiovascular profile. With its high selectivity for DPP—4
`and.its clin. and.cardiovascular profile, saxagliptin.is an attractive novel
`DPP—4 inhibitor.
`IT
`3\
`.x‘ %1~3, Saxagliptin
`RE: PAC (Pharmacological activity); THU (Therapeutic use); 3IOL
`(Eiologica' study); USES (Uses)
`(management of type 2 diabetes using saxagliptin)
`361442—04—8
`HCAPLUS
`
`RN
`
`CN
`
`2—Azabicyc;o[3.1.0]heXane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.1.13,7]dec—1—yl)acetyl]—,
`(1S,3S,5S)-
`(CA INDEX NAME)
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CTTTNG REF COUNT:
`
`RfibfiRfiNCfi COUNT:
`
`1
`
`45
`
`T1fiRfi ARfi 1 CAPIJS RTCORDS THAT CTTE T1TS RECORD
`(1 CTTTNGS)
`T1fiRfi ARfi 45 CTTfiD RfibfiRfiNCfiS VAT.A9.? FOR THIS
`RECOQD. ALL CTTATTORS AVATLAQLV TN Tifi Rfi EORMAT
`
`L49
`
`ANSWER 47 OF 87
`
`HCAPLUS
`
`COPYRIGHT 2012 ACS on STN
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:28)(cid:20)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-|PR2016-01104- Ex. 1006, Part 1, p. 191 of 259
`
`62
`
`0191
`0191
`
`

`
`13/308,658
`
`20l0:55l452
`154:291821
`
`HCAPLUS
`
`
`F ll"teXt
`
`Green process chemistry in the pharmaceutical industry
`Cue, 3erkeley W.; Zhang, Ji
`3WC Pharma Consulting, LLC, Ledyard, CT, USA
`Green Chemistry Letters and Reviews
`(2009), 2(4),
`193-211
`ISSN:
`CODEN: GCLRAI;
`Taylor & Francis Ltd
`Journal; General Re‘
`
`
`
`l75l-8253
`
`ACCESSION NU 3ER:
`DOCJ ENT NUMEER:
`
`TIT.E:
`AUT{OR(S).
`CORRORATE SOJRCE:
`SOJECE:
`
`?J3.ISHER:
`DOCUMENT TYPE:
`
`Eng'ish
`EAWGUAGE:
`04 May 2010
`«D
`«n:ered STN:
`A3
`A review. Key factors for deriving environmentally sustainable processes
`in the synthesis of pharmaceutical intermediates and products are discussed.
`The selection and use of solvents is emphasized.as regards methods to1ninimize
`environmental
`impact. Case studies of successful process development to
`attain improved green processes are included.
`3§1§§E“0¢ 8?, Saxagliptin
`RL: SPN (Synthetic preparation); THU (Therapeutic use); EIOL (Eiological
`study); PREP (Preparation); USES (Uses)
`(green orocess chemical
`in oharmaceutical
`361442—04—8
`HCAPLUS
`
`industry)
`
`IT
`
`RN
`
`CN
`
`2—Azabicyclo[3.1.0]heXane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.1.13,7]dec—1—yl)acetyl]—,
`(lS,3S,5S)-
`(CA INDnX NAMn)
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CITING REF COUNT:
`
`RntnRnNCn COUNT:
`
`6
`
`87
`
`T{nRn ARn 6 CAP.JS RECORDS THAT CITE TIIS RECORD
`(6 CITINGS)
`TinRn ARn 87 CITnD RntnRnNCnS VAI.A3.E FOR THIS
`RECORD. ALL CITATIORS AVAILAELE IN Tin Rn EORMAT
`
`ANSWER 48 OF 87
`L49
`ACCESSION NU 3ER:
`DOCJ ENT WUM3E%:
`
`COPYRIGHT 2012 ACS on STN
`HCAPLUS
`20lO:l394l9
`HCAPLUS Full"teXt
`l52:278405
`
`TIT.E:
`
`AUT{OR(S):
`
`CORROEATE SOURCE
`
`SOURCE:
`
`Medicinal Chemistry of Incretin Mimetics and DPP-4
`Inhibitors
`
`Zettl, Heiko; Schubert—Zsi;avecz, Manfred;
`Steinhilber, Dieter
`Institute of Pharmaceutical Chemistry,
`Goethe—University Frankfurt, Frankfurt/Main, 60438,
`Germany
`ChemMedChem (2010), 5(2), 179-185
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:28)(cid:21)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-|PR2016-01104- Ex. 1006, Part 1, p. 192 of 259
`
`63
`
`0192
`0192
`
`

`
`13/308,658
`
`ISSN: 1860-7179
`CODEN: CHEMGX;
`Wiley-VCH Verlag GmbH & Co. KGaA
`
`Journal; Gene al Review
`English
`03 Feb 2010
`
`?JELISHER:
`DOCUMENT TYPE:
`EANGUAGE:
`ED
`En:ered STN:
`A3
`
`IT
`
`RN
`
`CN
`
`
`;;D.s* -‘~8, Saxagliotin
`XL: D
`(Drug mechanism of action); PAC (Pharmacological activity); THU
`(Therapeutic use); EIOL (Eiological study); USES (Uses)
`(medicinal chemical of incretin mimetics and DPP—4 inhibitors)
`36l442—04—8
`HCAPLUS
`
`2—Azabicyclo[3.l.0]heXane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.l.l3,7]dec—l—yl)acetyl]—,
`(lS,3S,5S)-
`(CA INDEX NAME)
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CITING REF COUNT:
`
`REFERENCE COUNT:
`
`3
`
`39
`
`T{ERE ARE 3 CAP.JS RECORDS THAT CITE T{IS RECORD
`
`(3 CITINGS)
`T{ERE ARE 39 CITED REFERENCES VAI.AE.E FOR THIS
`RECORD. ALE CITATIORS AVAILAELE IN T{E RE FORMAT
`
`ANSWER 49 OF 87
`L49
`ACCESSION NU EER:
`DOCJ ENT NUMEER:
`
`COPYRIGHT 2012 ACS on STN
`HCAPLUS
`20lO:3l736
`HCAPEUS Fullutext
`l52:llO65O
`
`TIT.E-
`
`AUT{O%(S):
`CO%?O%ATE SOURCE:
`
`SOJRCE:
`
`?JE.ISHER:
`DOCJMENT TYPE:
`EANGUAGE:
`ED
`En:ered STN:
`
`Saxagliptin: a new DPP—4 inhibitor for the treatment
`of type 2 diabetes mellitus.
`[Erratum to document
`cited in CAl5l:394956]
`Tahrani, Abd A.; Piya, Milan K.; 3arnett, Anthony H.
`Jndergradua:e Center, 3irkingham {eartlands Hospital,
`Birmingham, 39 5SS, UK
`Advances in Therapy (2009), 26(7), 736
`CODEN: ADTHE7;
`ISSN: O74l-238X
`Springer Healthcare Communications
`Journal; General Review
`English
`ll Jan 2010
`
`A3
`
`in line 4,
`in paragraph I,
`in the right column,
`On page 252,
`A review.
`"Saxaglipton demonstrates greater..
`.compared with DPP—8/9).44", was
`and
`should read:
`incorrectly given,
`"Saxagliptin demonstrates greater
`(400- and
`selectivity for DPP—4 than for either the DPP—8 or DPP—9 enzymes
`75-fol
`d,
`respectively).
`46.
`The active metabolite of saxagliptin
`is two—foI
`3MS—5l0849)
`(
`_d less potent than the parent. Selectivity of
`sitagi_iptin and vildagi
`_iptin for DPP—4 is >2600 and 32—250—fold greater,
`64
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:28)(cid:22)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-lPR2
`016-01104- Ex. 1006, Part 1, p. 193 of 259
`
`0193
`0193
`
`

`
`13/308,658
`
`3oth saxagliptin and 3MS—5l0849
`respectively, compared with DPP—8/9.44.
`are also highly selective for inhibition of DPP—4 compared with a large panel
`of other proteases tested (>4000—fold).".
`3§i€72~0§“3,
`Saxagliptin
`RE: PAC (Pharmacological activity); THU (Therapeutic use); 3IOL
`(3iological study); USES (Uses)
`(new dipeptidylpeptidase—4 inhibitor, saxagliptin for treatment of type
`2 diabetes me1'itus (?rratum))
`36l442—04—8
`HCAPEUS
`
`2—Azabicyclo[3.l.0]heXane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.l.l3,7]dec—l—yl)acetyl]—,
`(lS,3S,5S)-
`(CA INDEX NAME)
`
`IT
`
`RN
`
`CN
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CITING REF COUNT:
`
`l
`
`THERE ARE l CAPLUS RECORDS THAT CITE THIS RECORD
`(l CITINGS)
`
`ANSWER 50 OF 87
`L49
`ACCESSION NU EER:
`DOCJ ENT NUMEER:
`
`COPYRIGHT 2012 ACS on STN
`HCAPLUS
`2009:l6073l5
`HCAPLUS Fullwtext
`l52:445498
`
`TIT.E:
`
`The intersection of safety and adherence: new
`incretin—based therapies in patients with type 2
`diabetes mellitus
`
`AUT{OR(S):
`CO%?O%ATE SOURCE:
`SOJQCE:
`
`?JE.ISHER:
`DOCJMENT TYPE:
`EANGUAGE:
`«D
`«n:ered STN:
`
`Zarowitz, Barbara J.; Conner, Christopher
`Omnicare,
`Inc., Livonia, MI, USA
`?harmacotherapy (2009), 29(l2, Pt. 2), 55S—67S
`CODEN: PHPYDQ;
`ISSN: 0277-0008
`?harmacotherapy Publications
`
`fie: “‘I Review
`Journal;
`English
`28 Dec 2009
`
`A3
`
`One of the challenges facing health care providers in the
`A review.
`treatment of patients with type 2 diabetes mellitus is maintaining the
`balance between achieving Hb Alc targets while simultaneously minimizing
`adverse events—most notably hypoglycemia and weight gain—that may neg.
`affect adherence to therapy and thus treatment outcomes.
`Incretin—based
`treatments, such as glucagon—like peptide—l
`(GLP—l)—receptor agonists and
`dipeptidyl peptidase—4 (DP?—4) inhibitors, are the newest class of therapies
`for the management of patients with type 2 diabetes. Data from.clin. trials
`in which liraglutide, exenatide, saxagliptin, or sitagliptin were employed
`as monotherapy or added to ongoing antidiabetic treatment indicate that the
`incr tin bas d th rapi s hav
`v ry low risk for the development of
`hypoglycemia and either decrease body weight
`(GLP—l—receptor agonists) or
`65
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:28)(cid:23)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-|PR2016-01104- Ex. 1006, Part 1, p. 194 of 259
`
`0194
`0194
`
`

`
`13/308,658
`
`are weight neutral (DPP—4 inhibitors). Decreased risk for hypoglycemia and
`weight gain may improve adherence. Avoiding weight gain, which is commonly
`associated with older oral antidiabetic agents and some insulins, also has
`the potential to decrease the risk for cardiovascular disease. Future
`pharmacoeconomic studies may demonstrate translation of these benefits into
`good cost-effectiveness for these therapies.
`3§;.s3“§§~S, Saxagliptin
`RE: PAC (Pharmacological activity); THU (Therapeutic use); 3IOL
`(3iological study); USES (Uses)
`(adherence to saxagliptin may be improved by its decreasing risk for
`hypoglycemia and weight gain in patient with type 2 diabetes mellitus)
`36l442—04—8
`HCAPLUS
`
`2—Azabicyclo[3.l.0]heXane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.l.l3,7]dec—l—yl)acetyl]—,
`(lS,3S,5S)-
`(CA INDEX NAME)
`
`IT
`
`RN
`
`CN
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CITING REF COUNT:
`
`REFERENCE COUNT:
`
`3
`
`88
`
`T{«R« ARE 3 CAP.JS RECORDS THAT CITE T{IS RECORD
`(3 CITINGS)
`T{fiR« ARE 88 CITED REFERENCES AVAI.AE.E FOR THIS
`RECORD. ALL CITATIORS AVAILAELE IN Tin Rn FORMAT
`
`ANSWER 51 OF 87
`L49
`ACCESSION NU EER:
`DOCJ ENT NUMEER:
`TIT.E:
`
`COPYRIGHT 2012 ACS on STN
`HCARLJS
`2009:l48082l
`HCAPLUS Fullwtext
`l53:277l3
`Exoloration of the DPP—4 inhibitors with a focus on
`
`AUT{OR(S):
`
`CORROQATE SOURCE:
`
`SOJRCE:
`
`?JR.ISHER:
`DOCUMENT TYPE:
`EANGUAGE:
`3
`«
`«n:ered STN:
`
`saxagliptin
`Shibrook, Jay H.; Colucci, Randall A.; Schwartz, Frank
`
`Ohio University College of Osteopathic Medicine
`(OJ-COM), Family Medicine, Athens, OH, 45701, USA
`Exoert Opinion on Pharmacotherapy (2009),
`l0(l7),
`2927-2934
`ISSN: 1465-6566
`CODEN: EOPHF7;
`Informa Healthcare
`Joirnal; General Review
`English
`30 Nov 2009
`
`A3
`
`3ackground: Type 2 diabetes (T2DM) has become a worldwide
`A review.
`epidemic. Despite a vast array of new compds.
`to treat T2DM,
`recommended
`treatment goals are consistentlyrnot achieved in this country thus suggesting
`a need to increase treatment options. Obj ctiv : To r vi w th rol of DPP—4
`inhibitors in treatment of T2DM with an emphasis on saxagliptin. Methods:
`66
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:28)(cid:24)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-|PR2016-01104- Ex. 1006, Part 1, p. 195 of 259
`
`0195
`0195
`
`

`
`13/308,658
`
`The authors discuss the role of this new class of medications in treatment
`
`of T2DM, review the current available studies and the unique characteristics
`of saxagliptin. Results and conclusions: Saxagliptin, a DPP—4 inhibitor,
`is one of an important new class of compds., which seems to be particularly
`safe and effective especially in early treatment of T2DM.
`fiT”““~0§~8, Saxagliptin
`
`RE: PAC (Pharmacological activity); THU (Therapeutic use); 3IOL
`(Eiologica' study); USES (Uses)
`(exploration of DPP-4 inhibitors with a focus on saxagliotin)
`361442—04—8
`HCAPEUS
`
`2—Azabicyclo[3.1.0]heXane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.1.13,7]dec—1—yl)acetyl]—,
`(lS,3S,5S)-
`(CA INDEX NAME)
`
`RN
`
`CN
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`<3 SI
`
`S
`
`NH2
`
`S
`
`OS.CITING REF COUNT:
`
`REFERENCE COUNT:
`
`3
`
`59
`
`T{nR« ARE 3 CAP.JS RECORDS THAT CITE TIIS RECORD
`(3 CITINGS)
`T{nRn ARE 59 CITED R«b«RnNCfiS AVAI.AE.E FOR THIS
`RECORD. ALL CITATIORS AVAILAELE IN Tin Rn FORMAT
`
`L49
`
`ANSWER 52 OF 87
`
`HCAPLUS
`
`COPYRIGHT 2012 ACS on STN
`
`ACCESSION NU EER:
`DOCJ ENT NUMEER:
`
`TIT.E:
`AUT{O%(S):
`CO%?O%ATE SOJQCE:
`SOJQCE:
`
`?JE.ISHER:
`DOCJMENT TYPE:
`EANGUAGE:
`«D
`«n:ered STN:
`
`2009:l438680
`l53:l3l
`
`HCAPLUS
`
`“‘.l~t—'t
`
`
`Saxagliptin
`Dhillon, Sohita; Weber, Juliane
`Adis,
`a Wolters Kluwer 3usiness, Auckland, N. Z.
`Drugs
`(2009), 69(15), 2103-2114
`CODEN: DRUGAY;
`ISSN: 0012-6667
`Adis Data Information 3V
`Journal; Qeneral Review
`English
`20 Nov 2009
`
`A3
`
`A review. Saxagliptin and its active metabolite M2 are dipeptidyl
`peptidase—4 inhibitors that improve glycemic control by preventing the
`inactivation of the incretin hormones glucagon—like peptide—1 (GLP—1) and
`glucose—dependent insulinotropic polypeptide. This increases GLP—1
`levels, stimulates insulin secretion and reduces postprandial glucagon and
`glucose levels.
`In well designed, 24—wk trials in treatment—naive patients
`with type 2 diabetes mellitus, monotherapy with oral saxagliptin 2.5 or 5
`mg once daily significantly improved glycemic control, as measured by mean
`glycosylated Hb
`(HbA1c)
`levels, relative to placebo.
`In large, well
`designed, 24—wk trials, combination therapy with saxagliptin.5 mg once daily
`plus metformin significantly improved HbA1c levels relative to single—agent
`67
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:28)(cid:25)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-|PR2016-01104- Ex. 1006, Part 1, p. 196 of 259
`
`0196
`0196
`
`

`
`13/308,658
`
`in
`
`the
`
`saxagliptin or metformin in treatment—naive patients;
`treatment—eXperienced patients with inadequate glycemic control,
`addition of saxagliptin 2.5 or 5 mg once daily to metformin,
`glyburide or
`a thiazolidinedione,
`significantly improved HbA1c levels rela:ive to
`continued use of existing monotherapy.
`Saxagliptin as monotherapy or in
`combination with.other oral antihyperglycemics was generallyrwell tolerated,
`with most adverse events being of nild.to moderate severity. In clin. trials,
`the incidence of hypoglycemic events in patients receiving saxagliptin was
`generally similar to that in patients receiving placebo or other oral
`antihyperglycemic agents. Saxagliptin therapy was not associated with an
`increased risk of cardiovascular events according to pooled data from eight
`_s.
`Saxagliptin generally had a weight—neutral effect.
`3Sisé$~Q§“S,
`Onglyza
`.
`RE:
`PAC (Pharmacological activity);
`USES
`(Uses)
`3iological study);
`(pharmacol.
`properties,
`clin. efficacy and tolerability of saxagliptin
`in patients with tyoe 2 diabetes)
`HCAPLUS
`361442-04-8
`
`(
`
`THU
`
`(Therapeutic use);
`
`3IOL
`
`RN
`CN
`
`2—Azabicyclo[3.1.0]hexane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.1.13,7]dec—1—yl)acetyl]—,
`(CA IND«X NAME)
`(lS,3S,5S)-
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CITING REF COUNT:
`
`Rnb«R«NC« COUNT:
`
`l7
`
`34
`
`T{«R« ARE l7 CAP.US RECORDS TPAT CITE THIS
`RECORD (l8 CITIRGS)
`T{«R« ARE 34 CITED R«b«RfiNCnS AVAILAR.E FOR THIS
`RECORD. ALL CITATIORS AVAILAELE IN T-« Rn FORMAT
`
`ANSWER 53 OF 87
`L49
`ACCESSION NU RER:
`DOCJ ENT VUMRER:
`
`COPYRIGHT 2012 ACS on STN
`HCAPLUS
`2009:l2l4747
`HCAPLUS Full—teZt
`l52:5627l5
`
`TIT.E:
`
`AUT{OR(S)
`
`COR?ORATE SOURCE
`SOJRCE:
`
`?UE.ISHER:
`DOCJMENT TYPE:
`EAWGUAGE:
`«D
`«n:ered STN:
`
`Inhibitor selectivity in the clinical application of
`dipeptidyl peptidase—4 inhibition
`<irby, Mark; Yu, Denise M. T.; O'Connor, Steven;
`Gorrell, Mar< D.
`Rristo'-Myers Squibb, Princeton, NJ, 08540, USA
`Clinical Science (2010), 118(1/2), 31-41
`CODEN: CSCIAE;
`ISSN: Ol43-5221
`?or:land Press Ltd.
`Journal; Qeneral Review
`English
`05 Oct 2009
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:28)(cid:26)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-IPRZO16-01104- Ex. 1006, Part 1, p. 197 of 259
`
`68
`
`0197
`0197
`
`

`
`13/308,658
`
`(dipeptidyl peptidas
`DPP—4
`A review.
`4) d grad s th incr tin hormones
`GLP—l
`(glucagon—like peptide—l) and GIP (gastric inhibitory polypeptide),
`
`In
`decreasing their stimulatory effects on B—cell insulin secretion.
`patients with Type22diab t s, m al r lat c1GLP l s cr tion.is reduced. DPP—4
`inhibitors (alogliptin, saxagliptin, sitagliptin and vildagliptin) correct
`the GLP—l deficiency by blocking this degradation, prolonging the incretin
`effect and enhancing glucose homoeostasis.
`DPP—4 is a member of a family
`of ubiquitous atypical serine proteases with many physiol. functions beyond
`incretin degradation, including effects on the endocrine and immune systems.
`The role of DPP—4 on the immune system relates to its extra—enzymic
`activities.
`The intracytosolic enzymes DPP—8 and DPP—9 are recently
`discovered DPP—4 family members. Although specific functions of DPP—8 and
`DPP—9 are unclear, a potential for adverse effects associated with DPP—8 and
`DPP—9 inhibition by non—selective DPP inhibitors has been posed based on a
`single adverse preclin. study.
`How v r, th pr pond ranc of data suggests
`that such DPP—8 and DPP—9 enzyme inhibition is probably without clin.
`consequence. This review examines the structure and function of the DPP—4
`family, associated.DPP—4 inhibitor selectivity and the implications of DPP—4
`inhibition in the treatment of Type 2 diabetes.
`S
`3S1§§§
`, Saxagliptin
`RE: PAC (Pharmacological activity);
`3iological study); USES (Uses)
`(inhibitor selectivity in the clin.
`peptidase—4 inhibition)
`36l442—04—8
`HCAPLUS
`
`THU (Therapeutic use); 3IOL
`
`application of dipep:idyl
`
`2—Azabicyclo[3.l.0]hexane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.l.l3,7]dec—l—yl)acetyl]—,
`(lS,3S,5S)-
`(CA IND«X NAM«)
`
`IT
`
`RN
`CN
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CITING REF COUNT:
`
`R«b«R«NCn COUNT:
`
`23
`
`55
`
`T{«Rn AR« 23 CAPIUS RECORDS TPAT CITE THIS
`
`RECORD (23 CITIRGS)
`T{nRn AR« 55 CITED R«bnRfiNCnS AVAILAR.E FOR THIS
`RECORD. ALL CITATIORS AVAILARLE IN Tin Rn FORMAT
`
`ANSWER 54 OF 87
`L49
`ACCESSION NU RER:
`DOCJ ENT VUMRER:
`
`COPYRIGHT 20l2 ACS on STN
`HCAPLUS
`2009:ll43086 HCAPLUS Fu1l~teXt
`l52:2540lO
`
`TIT.?:
`AUT{OR(S):
`COR?ORATE SOJRCE:
`
`Pharmacotherapy of hyperglycemia
`Kulasa, Kristen M.; Henry, Robert R.
`Veterans’ Affairs San Diego Healthcare System,
`Department of Medicine, University of California, San
`Diego, CA, 92161, USA
`
`69
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:28)(cid:27)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-IPRZO16-01104- Ex. 1006, Part 1, p. 198 of 259
`
`0198
`0198
`
`

`
`13/308,658
`
`SOJRCE:
`
`?J§LISHER:
`DOCUMENT TYPE:
`
`Expert Opinion on Pharmacotherapy (2009),
`2415-2432
`ISSN: 1465-6566
`CODnN: «OPHI7;
`Informa Healthcare
`Journal; General Review
`
`lO(l5),
`
`English
`EANGUAGE:
`18 Sep 2009
`«D
`«n:ered STN:
`A3
`A review. Type22diabe:es1ne"itus (T2DM) isa.chronic, progressive<iisorder
`that affects more than 230 mi"ion_people worldwide and is expected.to affect
`366 million by 2030. Both the prevalence of T2DM and the cost of its long
`term complications has driven the focus and emphasis on treatments aimed at
`reducing hyperglycemia and controlling hypertension and dyslipidemia.
`In
`the last 5 years new glucose lowering drugs acting on novel pathways have
`been developed,
`licensed and launched.
`These drugs include the
`glucagon—;ike peptide (GLP—l) agonists, exenatide, and.dipeptidyl peptidase
`(DPP—IV)
`inhibitors such as sitagliptin and saxagliptin. This review
`describes current approaches to T2DM treatment,
`focusing on newer agents
`which tend to be associated with less hypoglycemia and.possib;e weight loss,
`and addresses the potential roles of novel oral pharmacol. agents in the
`lat
`stag s of d v lopm nt that might provide new options for the management
`of this disease.
`
`IT
`
`RN
`
`CN
`
`3$l§§3~0§~3, Saxagliptin
`RE: PAC (Pharmacological activity); THU (Therapeutic use); 3IOL
`(3iological study); USES (Uses)
`(new agents of oral dipeptidyl peptidase—IV inhibitors sich as
`saxagliptin may be effective in controlling hyperglycemia in patient
`with type 2 diabetes mellitus)
`36l442—04—8
`HCAPLUS
`
`2—Azabicyclo[3.l.0]heXane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.l.l3,7]dec—l—yl)acetyl]—,
`(lS,3S,5S)-
`(CA INDnX NAMn)
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CITING REF COUNT:
`
`RnbnRnNCn COUNT:
`
`5
`
`99
`
`T{nRn ARE 5 CAP.JS RECORDS THAT CITE T{IS RECORD
`(5 CITINGS)
`T{nRn ARn 99 CITED RnbnRfiNCnS VAI.A3.E FOR THIS
`RECORD. ALL CITATIORS AVAILARLE IN Tin Rn FORMAT
`
`ANSWER 55 OF 87
`L49
`ACCESSION NU EER:
`DOCJ ENT WUMQER:
`
`COPYRIGHT 20l2 ACS on STN
`HCAPLUS
`2009:ll20506 HCAPLUS Full—teZt
`l52:44528l
`
`TIT.E:
`
`Clinical results of treating type 2 diabetic patients
`with sitagliptin, vildagliptin or saxagliptin —
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:20)(cid:28)(cid:28)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-|PR2016-01104- Ex. 1006, Part 1, p. 199 of 259
`
`70
`
`0199
`0199
`
`

`
`13/308,658
`
`diabetes control
`
`and potential adverse events
`
`Lund University,
`
`Endocrinology &
`
`AU
`CO
`
`THO
`RPO
`
`SO
`
`L*J
`JRCI:
`
`ELI
`?J
`SHER:
`DOCUMENT TYPE:
`.JA
`VGUAGE:
`".
`
`D 3
`
`A
`
`Ahren, 3o
`Department of Clinical Sciences,
`Eund, Swed.
`3es Practice & Research, Clinical
`etabolism (2009), 23(4), 487-498
`CODEN: RPRCE9
`Elsevier Ltd.
` Journal;
`English
`14 Sep 2009
`«n:ered STN:
`is a novel oral
`Inhibition of dipeptidyl peptidase—4 (DPP—4)
`A review.
`treatment for type2 diabetes.
`DPP—4 inhibition increases insulin secretion
`and reduces glucagon secretion by preventing the inactivation of
`Several
`glucagon—like peptide—l
`(GLP—l),
`thereby lowering glucose levels.
`DPP—4 inhibitors are in clin. development; more studies exist for sitagliptin
`and vildagliptin.
`They improve metabolic control
`in type 2 diabetes in
`monotherapy and also in combination with metformin, sulfonylurea and
`thiazolidinediones. HbAlc is reduced by approx. 0.6—l.l% in studies up to
`52 wk. Similar, although more limited, results were obtained for
`saxagliptin.
`DPP—4 inhibitors are safe and tolerable with no increased risk
`of adverse events compared to placebo and have a low risk of hypoglycemia.
`DPP—4 inhibitors are body weight—neutral.
`The DPP—4 inhibitors are
`recommended for use in the early stage of type 2 diabetes,
`in combination
`with metformin in subjects with inadequate glycemic control.
`DPP—4
`inhibition may also be used in combination with sulfonylurea and
`thiazolidinediones and potentially also in combination with insulin.
`durability and long—term safety of DPP—4 inhibitiors remain to be
`es
`
`Saxagliptin
`551»
`.4:
`Pharmacological activity);
`R
`(3iological study); USES (Uses)
`(novel oral treatment inhibiting DPP—4 using sitagliptin, vildagliptin
`or saxagliptin increased insulin,
`reduced glucagon secretion preventing
`inactivation of GLP—l
`lowering glucose level may be useful
`in patient
`with type 2 diabetes)
`36l442—04—8
`HCAPLUS
`
`The
`
`THU
`
`(Therapeutic use);
`
`3IOL
`
`IT
`
`RN
`CN
`
`2—Azabicyclo[3.l.0]hexane—3—carbonitrile,
`2—[(2S)—2—amino—2—(3—hydroxytricyclo[3.3.l.l3,7]dec—l—yl)acetyl]—,
`(lS,3S,5S)-
`(CA INDEX NAME)
`
`Absolute stereochemistry.
`
`HO
`
`CN
`
`S
`
`N
`
`S
`
`OS.CITING REF COUNT:
`
`23
`
`TH.
`
`. ARn 23 CAPLUS RECORDS THAT CITE THIS
`
`(cid:54)(cid:88)(cid:81)(cid:16)(cid:36)(cid:80)(cid:81)(cid:72)(cid:68)(cid:79)(cid:16)(cid:44)(cid:51)(cid:53)(cid:21)(cid:19)(cid:20)(cid:25)(cid:16)(cid:19)(cid:20)(cid:20)(cid:19)(cid:23)(cid:16)(cid:3)(cid:40)(cid:91)(cid:17)(cid:3)(cid:20)(cid:19)(cid:19)(cid:25)(cid:15)(cid:3)(cid:51)(cid:68)(cid:85)(cid:87)(cid:3)(cid:20)(cid:15)(cid:3)(cid:83)(cid:17)(cid:3)(cid:21)(cid:19)(cid:19)(cid:3)(cid:82)(cid:73)(cid:3)(cid:21)(cid:24)(cid:28)
`Sun-Amneal-|PR2016-01104- Ex. 1006, Part 1, p. 200 of 259
`
`71
`
`0200
`0200
`
`

`
`13/308,658
`
`RntnRnNCn COUNT:
`
`64
`
`RECORD (23 CITIRGS)
`1
`TinRn ARn 64 CITnD RntfiRnNCfiS AVAILAR E FOR THIS
`RECORD. ALL CITATIORS AVAILARLE IN Tin Rn tORMAT
`
`ANSWER 56 OF 87
`L49
`ACCESSION NU RER:
`DOCJ ENT NUMRER:
`
`COPYRIGHT 2012 ACS on STN
`HCAPLUS
`2009:700928
`HCAPLUS Fullmtext
`l5l:4845l8
`
`TIT.E:
`
`AUT{OR(S):
`L‘J
`COR?ORATE SOURC :
`
`L‘J
`SOJRCI'
`
`?JE.ISHER:
`DOCJMENT TYPE:
`EANGUAGE:
`«D
`«n:ered STN:
`
`Saxagliptin: a new dipeptidyl peptidase—4 inhibitor
`for the trea:ment of type 2 diabetes
`Deacon, Caro